MedTrace Logo

VQI DELTA Paclitaxel Device Safety Analysis

NCT04110288 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 219483

Last updated 2020-10-19

No results posted yet for this study

Summary

The VQI-DELTA Paclitaxel Device Safety Analysis seeks to assess the comparative safety of paclitaxel coated balloons and stents in the treatment of peripheral artery disease (PAD) through analysis of the VQI Peripheral Vascular Intervention (PVI) registry module using the DELTA system.

Conditions

  • Peripheral Vascular Disease

Interventions

DRUG

Paclitaxel

Paclitaxel to treat peripheral arterial disease

DEVICE

Non-drug coated Device Treatment

Sponsors & Collaborators

  • Society for Vascular Surgery Patient Safety Organization

    collaborator OTHER

  • Lahey Clinic

    lead OTHER

Principal Investigators

  • Frederic S Resnic, MD MSc · Lahey Hospital & Medical Center

  • Daniel Bertges, MD · Society for Vascuar Surgery Patient Safety Organization

  • Jens Eldrup-Jorgensen, MD · Society for Vascuar Surgery Patient Safety Organization

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2019-08-30
Completion
2020-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04110288 on ClinicalTrials.gov